DJIA 17,440.59 -127.94 -0.73%
NASDAQ 5,039.78 -48.85 -0.96%
S&P 500 2,067.64 -12.01 -0.58%
market minute promo

Celgene (NASDAQ: CELG)

132.56 -2.34 (-1.73%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

CELG $132.56 -1.73%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $133.45
Previous Close $134.90
Daily Range $131.11 - $133.45
52-Week Range $83.16 - $140.72
Market Cap $105.1B
P/E Ratio 45.57
Dividend (Yield) $0.00 (0.0%)
Volume 6,786,516
Average Daily Volume 4,969,384
Current FY EPS $4.22




Drug Makers

Celgene (CELG) Description

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Website:

News & Commentary Rss Feed

1 ETF That’s Crushing Even Warren Buffett

Warren Buffett's Berkshire Hathaway has rarely been beaten by any fund for lengthy periods of time. But this ETF is doing it in spades. Here's how.

Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog

Morgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks

Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground

Short Sellers Back Off Major Biotechs

FCX, CLF, BIIB, COF: Jim Cramer's Views

Biotech IPO Boom Gaining Thrust With NantKwest Debut

Seeking Alpha's Biotech Weekly: What Can Biogen Tell Us About The Sector?

Cramer: Biogen's Horseman May Have Fallen Off, But These 3 Are Better

Celgene Delivers as Expected in Q2, but Raises New Questions

Celgene once again trounces Wall Street's expectations in the second quarter, but this earnings report also came with a few surprises.

See More CELG News...

CELG's Top Competitors

CELG $132.56 (-1.73%)
Current stock: CELG
GILD $110.54 (-2.03%)
Current stock: GILD
$0.00 (0.00%)
Current stock:
BIIB $309.43 (3.13%)
Current stock: BIIB